Laboratory Billing and RCM in 2027: The Q4 Issues Every Lab Should Be Watching

The final quarter of 2026 is here, and laboratories have plenty to think about before January.

The PAMA data reporting period has ended. Laboratories are preparing for the 2027 Clinical Laboratory Fee Schedule. Artificial intelligence and automation continue moving deeper into healthcare operations. Molecular diagnostics, genetic testing, NGS and precision medicine continue advancing.

At the same time, familiar revenue cycle questions have not disappeared.

Are claims being paid correctly? Why are claims being denied? How much A/R is aging beyond 90 days? Are eligibility and authorization problems being caught early enough? Can laboratory leadership easily see what is happening across the revenue cycle?

For laboratory executives, these questions are becoming increasingly important as reimbursement, technology and payer requirements continue to change.

The final months of 2026 provide an opportunity to look closely at laboratory billing performance and prepare for 2027.

PAMA Reporting Is Over. What Happens Next?

One of the most important laboratory reimbursement milestones of 2026 occurred on July 31 when the PAMA data reporting period ended.

The applicable information reported during the 2026 reporting period will help determine payment rates under the Clinical Laboratory Fee Schedule for calendar years 2027 through 2029.

There is no PAMA phase in reduction for 2026.

Beginning January 1, 2027, however, applicable payment reductions resulting from private payer rate implementation may be as much as 15 percent compared with the payment amount established for the preceding year.

For laboratory executives, the bigger question is not simply what CMS will do. It is whether your laboratory understands its own financial performance well enough to respond.

What are you collecting by payer? What are you collecting by test? Where are your denials originating? How much revenue is sitting in aging A/R? Which payers create the most administrative work? How long does it take earned revenue to become cash?

Those answers provide the financial baseline laboratories need when reimbursement conditions change.

How Healthy Is Your Laboratory Revenue Cycle?

Q4 is an ideal time to understand where your revenue cycle stands before 2027. ADS can help you review billing performance, denials, aging A/R and opportunities to improve cash flow. Request a Laboratory Revenue Assessment.

The 2027 Clinical Laboratory Fee Schedule Deserves Attention

The Clinical Laboratory Fee Schedule affects reimbursement for thousands of laboratory tests paid by Medicare. That makes CLFS changes more than a regulatory issue. They are a business planning issue.

Laboratories should understand how changes in reimbursement may affect their individual test mix rather than relying solely on broad industry averages. A molecular diagnostics laboratory may have very different exposure from a toxicology laboratory. A pathology operation may have different reimbursement considerations from an independent clinical laboratory.

Payer mix matters. Test mix matters. Volume matters. The efficiency of the revenue cycle matters.

When reimbursement is under pressure, preventable revenue leakage becomes considerably more expensive.

Laboratory Revenue Cycle Management Is Moving Upstream

For years, laboratory billing was primarily associated with what happened after testing. Perform the test. Create the claim. Submit the claim. Wait for payment. Work the denial if necessary.

That model is changing.

Modern laboratory revenue cycle management increasingly begins before the claim is created. Patient information matters. Insurance information matters. Eligibility matters. Prior authorization may matter. Documentation matters. Medical necessity matters. Coding matters. Payer requirements matter.

When these issues are identified earlier, laboratory billing teams have a better opportunity to address them before they become denied claims.

The strongest denial strategy is not simply getting better at reworking denials. It is preventing as many avoidable denials as possible.

See What Modern Laboratory Billing Can Look Like

Explore laboratory billing technology and revenue cycle services designed for clinical, molecular, pathology, toxicology, genetics and NGS laboratories. Explore ADS Laboratory Billing Solutions.

Molecular Diagnostics and NGS Are Changing the Revenue Cycle Conversation

Scientific innovation continues moving quickly.

Molecular diagnostics, genetic testing, next generation sequencing and precision medicine are creating tremendous opportunities for laboratories and the clinicians and patients they serve.

They also create increasingly sophisticated billing workflows.

Depending on the test and payer, laboratories may need to navigate eligibility, authorization, documentation, medical necessity, coding and payer specific coverage requirements.

This means the financial workflow surrounding a sophisticated test needs to be sophisticated too.

The laboratory's billing operation should be able to identify potential problems early, track claims efficiently, recognize payer patterns and give leadership visibility into reimbursement.

This is especially important for molecular diagnostics billing, NGS billing and genetic testing billing, where administrative complexity can be significant and where laboratory billing software and RCM built for that complexity matters most.

AI in the Laboratory Is Not Just a Clinical Conversation

Artificial intelligence has become one of the most discussed technologies in laboratory medicine. Much of that conversation understandably focuses on science and clinical applications.

Laboratories should also be thinking about AI and automation in administrative workflows.

Revenue cycle teams spend enormous amounts of time reviewing information, checking payer responses, tracking claims, working denials, reconciling payments, following A/R and preparing reports.

Automation can help reduce repetitive administrative work and allow experienced billing professionals to focus on accounts requiring judgment and intervention.

The objective is not to remove people from laboratory billing. The objective is to give people better tools.

For laboratories struggling to recruit experienced billing personnel or control administrative costs, that distinction matters.

Laboratory Denial Management Needs to Become Denial Prevention

Every denial contains information. The question is whether the laboratory is learning from it.

If the same payer repeatedly denies claims for the same reason, that pattern should become visible. If authorization problems repeatedly occur with a certain test or payer, that information should reach the appropriate people earlier. If incorrect patient information creates recurring eligibility issues, the workflow should be examined upstream.

Denial management should therefore do more than organize rejected claims. It should provide intelligence that helps the laboratory prevent future problems.

A laboratory that becomes exceptionally efficient at fixing the same denial repeatedly has not necessarily solved the underlying problem. The better objective is fewer preventable denials.

What Are Your Denials Trying to Tell You?

ADS can help your laboratory examine denial patterns, aging A/R, payer performance and billing workflows to identify opportunities for improvement. Talk With a Laboratory RCM Specialist.

Why LIS Billing Integration Matters

The laboratory information system and the billing platform perform different jobs, but they depend on much of the same information.

When those systems do not communicate efficiently, people often become the connection. Staff members reenter data. They search for missing information. They reconcile records manually. They move between screens and spreadsheets.

Every manual step creates additional work and another opportunity for error.

LIS billing integration can help create a more efficient flow of information between laboratory operations and the revenue cycle.

ADS and ADSRCM can integrate with virtually any LIS or LIMS, helping laboratories connect operational and financial workflows.

For laboratories evaluating technology for 2027, integration should be a core consideration rather than an afterthought.

Have an LIS or LIMS Integration Question?

Talk with ADS about connecting your existing laboratory systems with your billing and revenue cycle workflows. Discuss Your Integration With ADS.

In House Laboratory Billing or Outsourced RCM?

Not every laboratory needs the same billing model.

Some laboratories have strong internal teams and want better laboratory billing software, automation, reporting and analytics. Others are finding it increasingly difficult to recruit, train and retain specialized billing personnel.

For those organizations, outsourced laboratory revenue cycle management may provide access to additional expertise while reducing administrative burden. Some laboratories may benefit from a combination of both approaches.

ADS supports in house laboratory billing technology as well as outsourced laboratory RCM through ADSRCM.

That allows the conversation to begin with what works for the laboratory rather than forcing every organization into the same model.

What Laboratory Executives Should Measure Before 2027

Laboratory leadership should enter 2027 with a clear understanding of revenue cycle performance.

That includes first pass or clean claim performance, denial rate, denial reasons, days in A/R, aging A/R, collections, payer performance and reimbursement trends.

The exact metrics will vary among laboratories. What should not vary is visibility.

Executives should not need to wait until someone manually assembles multiple spreadsheets to understand what is happening financially.

Laboratory billing technology should help turn revenue cycle information into business intelligence.

Meet ADS at AMP 2026

This November, ADS will join the molecular pathology community at the Association for Molecular Pathology Annual Meeting & Expo in Seattle.

AMP 2026 takes place November 10 through November 14.

The meeting will bring together laboratory professionals discussing genomics, molecular diagnostics, genetics, NGS, artificial intelligence, bioinformatics, precision medicine, coding, regulation and other issues shaping the future of laboratory medicine.

ADS will be there to discuss another important part of that future: how laboratories get paid for increasingly sophisticated testing.

ADS at AMP 2026

November 10 through 14 | Seattle

Visit ADS at Booth #1901

Bring us your questions about molecular diagnostics billing, NGS reimbursement, genetic testing billing, pathology billing, prior authorization, denial management, LIS integration, A/R or your current laboratory billing operation.

Schedule Time With ADS at AMP  |  Learn About ADS Laboratory Billing

Five Questions Every Laboratory Should Ask Before 2027

What are our most common denial reasons?

Denials should provide actionable information about weaknesses in the revenue cycle.

How much of our A/R is older than 90 days?

Aging receivables deserve attention before they become increasingly difficult to collect.

Which payers create the greatest reimbursement challenges?

Understanding payer performance can help laboratories prioritize revenue cycle resources.

Are eligibility and authorization problems being identified early enough?

Finding problems before testing or claim submission generally creates more options than discovering them after a denial.

Can our leadership team see meaningful revenue cycle KPIs?

Laboratory executives need financial visibility to make informed operational decisions.

If several of these questions are difficult to answer, Q4 is a good time to take a closer look.

Frequently Asked Questions About Laboratory Billing and RCM

What is laboratory revenue cycle management?

Laboratory revenue cycle management is the financial process surrounding laboratory testing, including patient and payer information, eligibility, claim submission, payment posting, denial management and accounts receivable follow up.

What is laboratory billing software?

Laboratory billing software helps clinical and diagnostic laboratories manage claims, payer requirements, remittances, denials, A/R, patient balances, reporting and other financial workflows associated with testing.

What is molecular diagnostics billing?

Molecular diagnostics billing involves managing coding, documentation, payer requirements, authorization and claims associated with molecular diagnostic testing.

What is NGS billing?

NGS billing refers to revenue cycle processes associated with next generation sequencing. These workflows may involve complex coding, coverage, medical necessity, documentation and payer requirements.

Why is laboratory denial management important?

Denial management helps laboratories identify unpaid claims, determine why they were denied and take appropriate action. An effective strategy also identifies recurring patterns so preventable denials can be addressed earlier.

Can laboratory billing software integrate with an LIS or LIMS?

Yes. Integration can help information move more efficiently between laboratory operations and financial workflows. ADS and ADSRCM can integrate with virtually any LIS or LIMS.

Should a laboratory outsource billing?

It depends on the laboratory's staffing, expertise, technology, test mix, payer mix and financial goals. Some laboratories benefit from maintaining billing internally with better technology, while others may benefit from outsourced laboratory RCM. ADS supports both approaches.

Prepare Your Laboratory for 2027

The laboratory industry will continue changing. Reimbursement will change. Technology will change. Testing will become more sophisticated. Payer requirements will continue evolving.

Laboratories cannot control every change. They can control how prepared their revenue cycle is to respond.

ADS and ADSRCM help clinical, molecular, genetics, pathology, toxicology, NGS and specialty laboratories improve financial performance through laboratory billing software, automation, analytics and specialized revenue cycle expertise.

Start 2027 With a Clearer Picture of Your Revenue Cycle

Let ADS take a closer look at your laboratory billing operation, denial trends, aging A/R and opportunities to improve collections and workflow efficiency. Request a Laboratory Revenue Assessment  |  Schedule a Personalized Demo.

Explore ADS Laboratory Billing Software and RCM Solutions